Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$58K Hold
2,018
﹤0.01% 1659
2026
Q1
$35K Sell
2,018
-1,508
-43% -$28.5K ﹤0.01% 1754
2025
Q4
$66K Hold
3,526
﹤0.01% 1525
2025
Q3
$51K Buy
3,526
+2,492
+241% +$35.5K ﹤0.01% 1640
2025
Q2
$20K Sell
1,034
-2,136
-67% -$38K ﹤0.01% 1707
2025
Q1
$56K Hold
3,170
﹤0.01% 1752
2024
Q4
$68K Hold
3,170
﹤0.01% 1746
2024
Q3
$99K Buy
+3,170
New +$78.9K ﹤0.01% 1292

Other funds holding CDNA

KBC Group's CDNA Position: Q2 2026 in Review

KBC Group held its CareDx (CDNA) position steady in Q2 2026 at 2,018 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

KBC Group first reported a position in CDNA in Q3 2024 and has held it in 8 quarters since. The position peaked at $99K in Q3 2024. 70 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

  • KBC Group held 2,018 shares of CareDx worth $58K as of Q2 2026.
  • KBC Group left its CareDx share count unchanged in Q2 2026.
  • CareDx made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1659 holding.
  • KBC Group first reported a position in CareDx in Q3 2024 and has held it in 8 quarters since.
  • KBC Group's CareDx position peaked at $99K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.